Vizsgálati helyszín
Hosp Univ Vall D Hebron
Barcelona, 08035, SpanyolországMég nincs intézményhez kötve
- 5futó vizsgálat
- 15lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis8 vizsgálat
- 3. fázis8 vizsgálat
- 1. fázis3 vizsgálat
- Állapot
- Lezárult14 vizsgálat
- Toboroz4 vizsgálat
- Fut, nem toboroz1 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC17 vizsgálat
- Actelion1 vizsgálat
- Janssen Pharmaceutica N.V., Belgium1 vizsgálat
- Johnson & Johnson Enterprise Innovation Inc.1 vizsgálat
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Toboroz
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
NCT05275023· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05455684· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection
NCT05123599· 1. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
NCT04882878· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
NCT04836559· 2. fázis· Janssen Research & Development, LLC· Forrás
Visszavonták
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
NCT04264806· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
NCT04657224· 1. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
NCT04535544· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
NCT04533529· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
NCT04439539· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT03904693· 3. fázis· Actelion· Forrás
Lezárult
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
NCT03573310· 1. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
NCT03301220· 3. fázis· Janssen Research & Development, LLC· Forrás
Hibát jelzek